Compare LITB & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | IMMP |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | Singapore | Australia |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 54.4M |
| IPO Year | 2013 | 2012 |
| Metric | LITB | IMMP |
|---|---|---|
| Price | $3.01 | $0.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 10.6K | ★ 594.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.50 | $445.09 |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.29 |
| 52 Week High | $4.17 | $3.53 |
| Indicator | LITB | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 44.89 |
| Support Level | $2.41 | $0.35 |
| Resistance Level | $3.89 | $0.56 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 27.81 | 69.60 |
LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.